B A C K G R O U N D
Malaria is a severe and debilitating disease caused by four species of the parasitic protozoan Plasmodium that are transmitted by many species of anopheline mosquitoes. Plasmodium falciparum is the most widespread and also the most serious and potentially fatal form. Recent estimates of the annual number of clinical malaria cases worldwide range from 214 to 397 million (WHO 2002; Breman 2004) , although a higher estimate of 515 million (range 300 to 660 million) clinical cases of P. falciparum in 2002 has been proposed (Snow 2005) . Annual mortality (nearly all from P. falciparum malaria) is thought to be around 1.1 million (WHO 2002; Breman 2004) . Malaria is believed to account for 3% of the world's total Disability Adjusted Life Years (DALYs) lost and 10% of DALYs in Africa (Breman 2004) . Malaria also significantly increases the risk of childhood death from other causes (Snow 2004) . Almost half of the world's population lives in areas where they are exposed to risk of malaria (Hay 2004) , and the increasing numbers of visitors to endemic areas are also at risk.
Despite continued efforts to control malaria, it remains a major health problem in many regions of the world, and new ways to prevent the disease are urgently needed. Early optimism for vaccines was tempered as the problems caused by genetic (hence, antigenic) variability of the parasite and the difficulty of generating high levels of durable immunity emerged. Recently, hope has been renewed by the development of several new vaccine candidates and delivery systems, as well as new formulations and adjuvants for previously existing candidates (Ballou 2004; Moorthy 2004) . Improved methods for screening the numerous vaccine candidates for efficacy have been developed (Druilhe 2005) . Vaccines currently under evaluation include recombinant proteins, synthetic peptides (including multiple antigen peptides), DNA vaccines, inactivated whole parasites, and vaccines comprising mixtures of a large variety of potential antigens.
To be effective, a malaria vaccine could either prevent infection altogether or mitigate against severe disease and death in those who become infected despite vaccination. Four stages of the malaria parasite's life cycle have been the targets of vaccine development efforts. The first two stages are often grouped as 'pre-erythrocytic stages' (ie before the parasite invades the human red blood cells): these are the sporozoites inoculated by the mosquito into the human bloodstream, and the parasites developing inside human liver cells. The other two targets are the stage when the parasite is invading or growing in the red blood cells (blood, merozoite, or erythrocytic stage); and the gametocyte stage, when the parasites emerge from red blood cells and fuse to form a zygote inside the mosquito vector (gametocyte, gamete, or sexual stage). Vaccines based on the pre-erythrocytic stages usually aim to completely prevent in-fection, while blood-stage vaccines aim to reduce (and preferably eliminate) the parasite load once a person has been infected. Gametocyte vaccines would prevent the parasite being transmitted to others through mosquitoes. Ideally, a vaccine effective at all these parasite stages is desirable (Richie 2002) .
Given the complexity and wide range of malaria vaccines under development, we have chosen to consider them in separate categories: blood-stage vaccines (the subject of this review); SPf66 vaccine; and pre-erythrocytic vaccines. Multi-stage vaccines, such as combined pre-erythrocytic and blood-stage vaccines (Reber-Liske 1995; Sturchler 1995) , and transmission-blocking vaccines will be included in future reviews.
The SPf66 vaccine was the first to be tested extensively (Graves 2006a). SPf66 was ineffective in Africa (five trials) and Asia (one trial). It had marginal efficacy in South America (four trials). SPf66 is no longer being tested, and development towards commercialization is not taking place. However, it is possible that new formulations of SPf66 or combinations with other antigens will be developed in the future. Results with one pre-erythrocytic vaccine, RTS,S, were more encouraging. In four trials, it was effective in preventing a significant number of clinical malaria episodes, including good protection against severe malaria in children, with no serious adverse effects (Graves 2006b).
This review includes trials of blood (asexual)-stage vaccines. The first blood-stage vaccine to be tested in challenge trials is MSP/RESA, known as Combination B. This vaccine is a mixture of three recombinant asexual blood-stage antigens: parts of two merozoite surface proteins (MSP1 and MSP2) together with a part of the ring-infected erythrocyte surface antigen (RESA), which is found on the inner surface of the infected red cell membrane. The MSP1 antigen is a 175 amino acid fragment of the relatively conserved blocks 3 and 4 of the K1 parasite line; it also includes a Tcell epitope from the P. falciparum circumsporozoite (CS) protein as part of the MSP1 fusion protein. The MSP2 protein includes the nearly complete sequence from one allelic form (3D7) of the polymorphic MSP2 protein. The RESA antigen consists of 70% of the native protein from the C-terminal end of the molecule.
Many other potential asexual stage vaccines are currently undergoing preclinical evaluation (see WHO 2005) . The proteins from which they are derived include:
• AMA1: recombinant apical membrane antigen 1 from the merozoite.
• MSP1, MSP2, MSP3, MSP4, and MSP5: merozoite surface proteins or portions thereof (eg MSP1(19), MSP1(42)), either recombinant or synthetic peptides.
• GLURP: glutamate-rich protein, recombinant or synthetic peptide, alone or combined with MSP3.
• RAP2: recombinant rhoptry-associated protein 2 (the rhoptry is an organelle in the merozoite).
• EBA-175, EBP2, MAEBL, and DBP: erythrocyte binding proteins involved in parasite invasion.
• PfEMP1: recombinant erythrocyte membrane protein, an antigen present on the surface of infected red blood cells.
Of these blood-stage antigens, a few also occur in pre-erythrocytic stages (GLURP, EBA-175, and MAEBL). Several antigens (AMA1, MSP1(19), MSP1(42), and a MSP peptide) have been tested in Phase 1 safety and immunogenicity trials excluded from this review. A Phase 2 trial of MSP1(42) (also known as FMP1) is in progress in Kenya (Stoute 2006) . Trials with these other bloodstage vaccines will be included as the results of randomized efficacy trials become available. MSP1-based and AMA-1 based antigens are also being tested in combination with antigens from pre-erythrocyte stages (Heppner 2005) .
O B J E C T I V E S
To assess the effect of blood-stage malaria vaccines in preventing infection, disease, and death.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials.
Types of participants
People of any age.
Types of interventions Intervention
Recombinant, synthetic peptide, parasite-derived, or other vaccines containing antigens from blood (asexual) stages of any species of malaria parasite tested in humans in artificial or natural challenge trials.
Types of outcome measures

Primary
• Clinical malaria episodes.
• Parasite density.
Secondary
• New malaria infection.
• Prevalence of parasitaemia.
• Fever episodes.
• Anaemia.
• Cerebral malaria.
• Severe malaria.
• Admission to hospital.
• Admission to hospital with diagnosis of malaria.
• Death.
• Adverse events.
Search methods for identification of studies
We have attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press , and in progress).
Databases
We searched the following databases using the search terms and strategy described in 
Reference lists
We checked the reference lists of all studies identified by the above methods.
Data collection and analysis
Selection of studies
Both authors independently applied the inclusion criteria to all identified trials. Differences were discussed until consensus was reached.
Data extraction and management
Both authors independently extracted data from the included trials using a pre-designed form. Differences found were discussed between the authors and errors corrected. Data that were not clear were checked with the authors for Saul 1999a, Saul 1999b, and Genton 2002.
Assessment of risk of bias in included studies
Both authors independently assessed the trials for four dimensions of quality using a pre-specified form: method of generation of allocation sequence and allocation concealment (adequate, inadequate, not done, or unclear as defined by Jüni 2001); blinding (described who was blinded, eg participants, investigators, and outcome assessors); and completion of follow up (proportion of those randomized who completed all doses and who completed follow up, if stated). Differences were discussed until consensus was reached. Trial details were checked with the authors for Saul 1999a, Saul 1999b, and Lawrence 2000.
Data synthesis
We analysed the data using Review Manager 5. Results for dichotomous data were expressed as risk ratios (RR) of an outcome occurring in the vaccine group compared to the placebo group. The risk ratio may be converted to an estimate of vaccine efficacy (also known as risk ratio reduction): efficacy = (1 -RR) x 100%.
Similarly, the 95% confidence interval (CI) for the vaccine efficacy (risk ratio reduction) may be obtained by substituting the upper and lower 95% confidence interval of the risk ratio into the formula. Continuous results (parasite density) were expressed as mean differences (MD), using the geometric mean parasite density in positive blood samples. If trials continued for more than one year (with or without booster dose), we separated the analysis of these results according to the year of follow up. It was prespecified that subgroup analysis could be performed according to geographical area or intensity of transmission, if appropriate. It was not prespecified that subgrouping would be done based on whether or not the participants were pretreated with antimalarial drugs. However this had an important effect on the results in one trial and therefore such subgrouping was done.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification. Five trials of MSP/RESA vaccine (Combination B) including 217 participants met the inclusion criteria; see the 'Characteristics of included studies' for more detailed information. Six trials were excluded; see the 'Characteristics of excluded studies'. One safety and immunogenicity trial of MSP1 in Kenya is in press (Stoute 2006). We will include it in an update of this review if and when an efficacy trial of the vaccine is completed. Of the five included trials, three assessed safety (and immunogenicity) only, and two tested efficacy as well as safety. Three were small trials in non-immune adults: two of these assessed safety only (Saul 1999a; Saul 1999b) ; and one assessed safety and efficacy against experimental challenge (Lawrence 2000). The two other trials had immune participants in Papua New Guinea: one was a small safety trial in 12 immune adults (Genton 2000) , and the largest trial (120 participants) assessed safety and efficacy in semiimmune children aged five to nine years exposed to natural challenge (Genton 2002). All trials used vaccine in Montanide ISA 720 adjuvant.
Safety trials
The first two randomized controlled trials, Saul 1999a and Saul 1999b, were small dose-finding studies that reported on safety and immunogenicity in non-immune adults (32 and 36 participants respectively). The first dose tested was 100 µg of each antigen, either mixed in one injection site or divided into three sites. Because of adverse effects in initial participants (see below) the dose was reduced to 50 µg (20 µg in the second dose) for remaining participants in the first trial, and to 50 µg, 13 µg, or 4 µg of each antigen per dose in the second trial. A dose of 13 to 15 µg of each antigen was used in the three subsequent trials. The safety trial of Genton 2000 included 12 semi-immune adults in Papua New Guinea who were moved to a non-endemic area for the duration of the trial (six weeks) to monitor adverse events. This trial used 15 µg of each antigen (total 45 µg) in each of two doses.
Safety and efficacy trials
The first MSP/RESA efficacy trial, Lawrence 2000, was in 17 non-immune adult Australians using experimental challenge with blood-stage parasites. In this trial, the primary outcome measure was the growth rate of the parasites after artificial challenge with blood-stage parasites injected intravenously, assessed by polymerase chain reaction (PCR). All participants had malaria parasites detected by PCR by day eight after the challenge, when they were all treated even though symptoms had not yet developed. The second safety and efficacy trial, Genton 2002, was in 120 Papua New Guinea children aged five to nine years exposed to natural challenge. The primary outcome measures were parasite density (geometric mean in positive samples) and change in ratio of different parasite variants (response to the variants whose genetic material was included in the vaccine was expected to be better than response to other variants). Active surveillance was by weekly home visits from week eight to 76 for suspected cases, with blood samples taken from all children every two weeks from weeks eight to 18. Passive surveillance for clinical episodes reporting to health facilities was also done. Extensive safety data were also collected. Because of debate over whether children should be pretreated for malaria before vaccination, half of the participants were treated with sulfadoxine-pyrimethamine (an effective drug in that population), and the results analysed separately by these subgroups.
Risk of bias in included studies
The method of randomization (allocation sequence) was by computer-generated random assignment in all trials. In the Saul 1999a trial, participants were initially randomly divided into three groups that were vaccinated sequentially, but screening and scheduling arrangements led to some reassignment between groups. Two in each group were randomly chosen to receive placebo. The Genton 2002 trial used randomization within age-stratified blocks of 12 so that vaccines could be given in a staggered manner while assessing safety. The Genton 2002 trial was also adequate for allocation concealment, while this was unclear in the other trials. The three trials that only examined safety and immunogenicity blinded only the participants (Saul 1999a; Saul 1999b; Genton 2000) , and the two trials that also assessed efficacy were double blind (Lawrence 2000; Genton 2002).
All the MSP/RESA trials were high quality in terms of losses to follow up. All participants completed the initial safety trials (Saul 1999a; Saul 1999b; Genton 2000) and the experimental challenge trial (Lawrence 2000). However, one participant in the placebo group in the Saul 1999a trial inadvertently received vaccine instead of placebo at the first dose. This person received vaccine at the second dose and was subsequently treated as a member of that group. Two participants in the Saul 1999b trial did not receive the second dose of vaccine due to adverse effects after the first dose but completed all the follow up. In the larger natural challenge trial (Genton 2002), 91% of all clinical assessments (7532 visits) and all but one of the planned 1080 blood samples (99.9%) were completed over a period of 76 weeks. The analysis was based on the total number of children randomized into the trial (120).
Effects of interventions
Criteria for judging the effectiveness of blood-stage vaccines are different from the pre-erythrocytic vaccines. With the latter, the aim is to prevent a patent infection from occurring at all, while with blood-stage vaccines, the aim is to reduce parasite density, which should translate to a reduction in number of clinical attacks or symptom severity.
Efficacy
Lawrence 2000 and Genton 2002 measured efficacy, but only Genton 2002 provided data that could be reported in the review. Genton 2002 is the only trial to date that has assessed a bloodstage vaccine with natural challenge. The results showed extreme heterogeneity between groups of children who were or who were not pretreated with an antimalarial (sulfadoxine-pyrimethamine). As a result, these two subgroups could not be combined in the meta-analyses for most outcome measures.
Parasite density
Parasite density was significantly lower in the vaccine group than in the placebo group, in the group that was not pretreated with sulfadoxine-pyrimethamine (MD -238.00, 95% -238.95 to -237.05; 31 participants, Analysis 1.1). The opposite trend was observed in the group that was treated with sulfadoxine-pyrimethamine (MD 432.30, 95% 429.99 to 434.61; 16 participants, Analysis 1.1), but this was complicated by the fact that in this sub-arm of the trial at baseline the vaccine group had a ten-fold higher parasite density than the placebo group.
Clinical malaria episodes
There was no evidence for an effect of the vaccine against episodes of clinical malaria in either the group pretreated with the antimalarial (60 participants) or the group with no antimalarial (60 participants) (Analysis 1.2); the results for these subgroups tended in the opposite direction.
New malaria infections
The trialists reported the effect of the vaccine on different parasite subtypes (detected by PCR); see Analysis 1.3. The vaccine was of the 3D7 MSP2 allelic type and vaccinees had a significantly fewer new malaria infections with the 3D7 type (RR 0.52, 95% CI 0.28 to 0.99; 120 participants). The number of infections measured with FC27, the other allelic type (not included in the vaccine), was not reduced by vaccination (120 participants). These effects were seen in both the groups with and without pretreatment with sulfadoxine-pyrimethamine (combined results are given in the analyses).
Prevalence of parasitaemia
Prevalence of parasitaemia (as assessed by blood slide) was lower in the group that was not pretreated with an antimalarial (60 participants) than the group that used sulfadoxine-pyrimethamine (60 participants), but neither result was statistically significant ( Analysis 1.4). In an analysis of the effect of the vaccine on different parasite subtypes (detected by PCR) (see Analysis 1.5), the vaccinees had a significantly lower prevalence of the 3D7 type (included in the vaccine) than did placebo recipients (RR 0.38, 95% CI 0.26 to 0.57; 719 participants). The prevalence of FC27, the other allelic type (not included in the vaccine), was not reduced by vaccination (720 participants). These effects were seen in both the groups with and without pretreatment with sulfadoxine-pyrimethamine (combined results are given in the analyses).
Safety
All five trials contributed safety data to the review. The plan in the first MSP/RESA trial was to give 100 µg of each antigen at each of two doses (Saul 1999a). However, due to adverse effects at these doses, only the first two-thirds of the 32 participants received this amount at the first dose. Significant pain and swelling in the injected thigh in one of these participants developed 12 days after first vaccination. The second dose was reduced to 20 µg of each antigen and even at that dose a hard painful lump developed at the injection site in the same volunteer six weeks after the second dose, causing difficulty in walking. Two other participants developed moderately severe delayed reactions to the vaccine, even when antigens were given in separate sites. In the second trial (Saul 1999b), doses were reduced to 4, 25, or 50 µg of each antigen or equivalent amount of placebo. In the 50 µg group, one vaccine participant developed severe pain in the injected thigh and one other developed a severe delayed reaction of pain and swelling in the injected leg. Overall in the two trials using 50 to 100 µg doses (Saul 1999a; Saul 1999b), there were four severe and four moderate local reactions, all in participants receiving vaccine rather than placebo. All the severe reactions resolved and there were no severe systemic reactions or sequelae. All three subsequent trials used a lower dose of 13 to 15 µg of each antigen per dose (Lawrence 2000; Genton 2000; Genton 2002). For the purposes of this review, we have tabulated only adverse events occurring in the three trials using the 13 to 15 µg doses, shown graphically in Analysis 1.6 and Analysis 1.7. The results represent the sum of events occurring after each of two doses. There were no significant differences between vaccine and placebo groups in the frequency of local or systemic adverse events of any severity (Analysis 1.6) or events of moderate severity including fever and pain or swelling at the injection site (Analysis 1.7). The most frequent adverse events reported were injection site pain, tenderness, and swelling. No serious or severe adverse events occurred in these three trials using 13 to 15 µg doses.
D I S C U S S I O N
This review describes the results of several relatively small trials of safety and efficacy of a blood-stage malaria vaccine. A small efficacy trial in non-immune adults with experimental challenge showed no effect (Lawrence 2000). In the single natural-challenge efficacy trial of MSP/RESA vaccine (Combination B) in semiimmune children (Genton 2002), no effect on clinical malaria infections was detected. However, parasite density was significantly reduced in the vaccinated children who were not pretreated with sulfadoxine-pyrimethamine. Also, in these children there was a reduction in the proportion of children with medium and high parasitaemia levels. The necessity of subgrouping by pretreatment status, together with imbalance in parasite density at baseline and heterogeneity, reduced the expected power of this trial.
The MSP/RESA vaccine (Combination B) contains three bloodstage antigens − MSP1, MSP2, and RESA. MSP2 has two major allelic forms (3D7 and FC27). Vaccinees in the Genton 2002 trial had a lower incidence and prevalence of parasites with the 3D7 type of MSP2 (the type included in the vaccine) than the placebo group, and a higher incidence of malaria episodes were associated with the FC27 type of MSP2. The investigators noted that efforts should be made to include all significant allelic types in a future vaccine. Also, the relative role of the three vaccine constituents cannot be assessed when based on the trials that have been carried out to date.
An issue explored by the Genton 2002 trial is the advisability of clearing parasitaemia with drug treatment before a trial commences. In this trial, significant efficacy was only observable in the group who were not pretreated with sulfadoxine-pyrimethamine. Since pretreatment with this antimalarial clearly reduces infection it enables incidence of new infections to be more easily determined, but this strategy also reduces power to detect changes in prevalence.
The results from the Genton 2002 trial have had a large impact on the design of blood-stage vaccine trials. In particular, the observation that the frequency of high or medium density infections was reduced by vaccination (in children not pretreated with sulfadoxine-pyrimethamine) has led to the likely inclusion of a similar outcome in future trials.
The results from trials of vaccines from other malaria life stages are described in separate Cochrane Reviews. In brief, the SPf66 vaccine showed early promise, but eventually it was determined to be ineffective in African children and only marginally effective in South America (Graves 2006a). The pre-erythrocytic vaccine RTS,S is showing encouraging results, with approximately 26% efficacy against malaria episodes and an estimated 58% efficacy against severe malaria in children (Graves 2006b). There is not enough evidence yet to determine whether MSP/RESA or other blood-stage vaccines currently being tested will be superior or equal to the now obsolete SPf66 vaccine or to the pre-erythrocytic vaccine RTS,S. Prevailing opinion today is that multi-stage vaccines, with antigens from several stages combined, are likely to be most effective. Results of multi-stage vaccine trials will be covered in a separate Cochrane Review as they become available.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Blood-stage malaria vaccines are not currently licensed for use. It is thus too early to evaluate implications for practice.
Implications for research
Based on the MSP/RESA results, blood-stage vaccines show promise. Further development of the vaccine should include adding the other main allelic form of MSP2, and the relative contribution of the other antigens in the vaccine should be clarified. Pretreatment of the participants during a vaccine trial has a large effect on the results, and the desirability of this practice for bloodstage vaccine trials needs to be resolved.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Genton 2000
Methods
Randomized controlled trial Generation of allocation sequence: computer-generated list Location: Goroka and Wosera, Papua New Guinea; participants were moved to Goroka (non-endemic area) during immunization Method of surveillance: observation by physician for 6 h after immunization, daily visits for 2 weeks; weekly observation for 6 weeks
Genton 2002
Methods Randomized controlled trial Generation of allocation sequence: computer generated; randomized in blocks of 12 within age group (5 to < 7.5 and 7.5 to < 10 years), 3 into each of 4 groups (vaccine/placebo, pretreated/not treated with sulfadoxine-pyrimethamine) Allocation concealment: code generated externally; vials indistinguishable and labelled only with code by independent preparers Blinding: double blind Inclusion of all randomized participants: 99.9% participation in blood sampling to week 18; 91% participation in morbidity surveillance to week 76 Length of follow up: 68 weeks after second immunization Participants Number: 120 children Inclusion criteria: age 5 to 9 years; parental consent Exclusion criteria: allergic predisposition; acute illness on day of screening; chronic illness; impaired liver or kidney function 
D A T A A N D A N A L Y S E S
